The charismatic and innovative Fletcher Wilson, founder and former CEO of Fogarty graduate company InterVene, made a big shift in his career during COVID. While he remains on the board of InterVene, he returned to his entrepreneurial roots and is now co-founder and...
When an employee on the job feels the onset of flu or COVID symptoms, their first step is usually to make a doctor’s appointment. By the time they visit a clinic and receive tests and a diagnosis, at least one and usually more days have passed, leading to multiple...
As Fogarty Innovation’s Company Accelerator Program (CAP) wraps up its first year, it is pleased to celebrate the graduation of Flosonics, which developed FloPatch, a low cost, easy-to-use, wearable Doppler ultrasound sensor that is improving the management of...
Fogarty Innovation’s Company Accelerator Program (CAP) is off to a strong start, celebrating the graduation of its first startups, Flosonics and UltraSight. The latter has developed an artificial intelligence-driven software designed to allow clinicians who aren’t...
Strokes are a leading cause of disability and the fifth leading cause of death in the United States. Of the nearly 800,000 people who suffer from a stroke in the U.S. each year, 87% are ischemic strokes, in which blood flow to the brain is blocked, according to...
Alydia Health was one of the first Companies-in-Residence at Fogarty Innovation and one the organization has been deeply passionate about, with its promise to solve postpartum hemorrhage (PPH). An enormous unmet need, PPH is the leading cause of maternal...
Our motto at Fogarty Innovation is “Innovation is best learned by doing.” It’s something you see at the organization every day, and that includes our incubation and acceleration programs, which are tailored to match the development stages of the entrepreneurs who...
The phrase “listen to your gut” will soon take on a whole new meaning for millions of practitioners and their patients, thanks to G-Tech, the Fogarty Innovation company that is developing a low-cost diagnostic solution for patients with chronic gastrointestinal...
Women’s healthcare continues to attract much-deserved investor attention. Subsequent to Fogarty graduate Alydia Health’s acquisition by Merck’s spinoff Organon, another Fogarty company, Materna Medical, announced it has raised $10 million in a Series A2 financing...
Approximately 100,000 U.S. patients require a kidney transplant each year, with some waiting more than five years for a donor, and up to half of those dying in the interim. And even for the “lucky” ones who receive a transplant, there are still hurdles. In fact, one...